Piracetam
Sponsors
University of Pennsylvania, Beersheva Mental Health Center, UCB Pharma, UCB S.A. - Pharma Sector, Hannover Medical School
Conditions
Acute Ischaemic Middle Cerebral Artery StrokeAnxiety DisordersCOVID-19Cocaine-Related DisordersDementiaDepressionDiabetic Peripheral NeuropathyDrug Adherence Marker
Phase 1
Phase 3
Phase 4
A Study to Evaluate the Efficacy and Safety of Piracetam on Aphasia After Acute Ischemic Cerebral Artery Stroke
TerminatedNCT01883011
Start: 1998-08-31End: 2001-07-31Updated: 2013-08-30
Subtherapeutic Dose of Piracetam as a Therapy Adherence Marker
NCT05918341
Start: 2023-07-03End: 2023-09-30Target: 10Updated: 2023-06-26
The Effect of Piracetam on Diabetic Peripheral Neuropathy Patients
Not yet recruitingNCT06479629
Start: 2025-02-10End: 2025-11-01Target: 60Updated: 2025-01-28
Unknown Phase
Efficacy and Safety of Piracetam Taken for 12 Months in Subjects Suffering From Mild Cognitive Impairment (MCI)
CompletedNCT00567060
Start: 2000-05-31End: 2004-01-31Updated: 2013-12-16
Different Treatment Options Used for Post Covid-19 Syndrome
CompletedNCT07722000
Start: 2021-02-01End: 2023-12-01Updated: 2026-07-28